Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 23Breast Neoplasms 22Carcinoma, Non-Small-Cell Lung 17Rectal Neoplasms 13Prostatic Neoplasms 13Gliosarcoma 12Lung Neoplasms 10Head and Neck Neoplasms 10Esophageal Neoplasms 10Brain Neoplasms 10Neoplasms 9Uterine Cervical Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Adenocarcinoma Of Esophagus 8Sarcoma 7Neoplasm Metastasis 7Central Nervous System Neoplasms 7Pancreatic Neoplasms 6Melanoma 6Glioma 6Carcinoma, Squamous Cell 6Astrocytoma 6Urinary Bladder Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Burkitt Lymphoma 5Oropharyngeal Neoplasms 4Medulloblastoma 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid, Acute 4

Interventions

Radiation 1Paclitaxel 1Chemoradiotherapy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Resectable Esophageal Cancer × Radiation × Clear all
NCT03490292 2024-07-26

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

University of Wisconsin, Madison

Phase 1/2 Completed
22 enrolled 17 charts
Gastrointestinal

Resectable Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡